Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML

Magee GH, Grunwald MR

In this review article, the authors discussed how the integration of next-generation sequencing and advanced cytogenetic diagnostics into routine clinical practice is reshaping frontline treatment in both fit and unfit patients with acute myeloid leukemia. With the continued evolution of the therapeutic landscape for acute myeloid leukemia continues to evolve, timely molecular characterization is essential for optimizing outcomes and choosing the most appropriate frontline strategy.